FDA Clears Twiist Pump for Type 2 Diabetes

Automated insulin delivery keeps widening its reach into type 2 diabetes — and it keeps doing so through 510(k) supplements rather than fresh premarket approvals. On 16 October 2026, FDA cleared an expanded indication for Sequel Med Tech's twiist system, extending a device cleared for type 1 diabetes in March 2024 to adults 18 and older with insulin-treated type 2 diabetes, backed by a 307-patient trial.

What changed, and what didn't

This is an indication expansion, not a new device authorization. Twiist's underlying hardware — the pump, its 300-unit reservoir, its CGM interoperability — is unchanged from the system FDA cleared for type 1 diabetes in March 2024. What changed is the population the labeling now covers: adults with insulin-treated type 2 diabetes, a population whose glycemic management differs in important ways from type 1 (generally less insulin sensitivity variability, different hypoglycemia risk profiles, and often concurrent oral or injectable non-insulin therapies). FDA's clearance of that broader population through a 510(k) supplement, rather than requiring a new premarket approval application, is itself the operational signal worth tracking: the agency continues to treat an AID system's move into type 2 diabetes as an indication-and-labeling question answerable with clinical data, not a different regulatory class.

The trial behind the expansion

The clearance rests on a 13-week multicenter trial enrolling 307 participants with insulin-treated type 2 diabetes. Average HbA1c improved by approximately 0.7 percentage points over the study period. Time in the 70–180 mg/dL target glucose range — the standard continuous-glucose-monitoring benchmark — rose from about 57% to 73%. No severe hypoglycemia events were reported during the trial. Those figures come from Sequel's own characterization of the study as reported in trade coverage; this outlet has not independently reviewed the underlying clinical study report or any peer-reviewed publication of the full dataset.

A category, not a one-off

Twiist is not the first automated insulin delivery system to clear for type 2 diabetes. Insulet's Omnipod 5 and Tandem Diabetes Care's t:slim X2 already carry that indication, meaning twiist's expansion is the third major system in the category rather than a category-opening event. For regulatory and quality teams at competing or adjacent device makers, the relevant precedent is less the specific trial numbers than the pathway: FDA continues to accept 510(k) submissions, supported by population-specific clinical data, as sufficient for AID-to-type-2 expansions, rather than treating each one as warranting a new predicate discussion or a PMA-level review. Sequel estimates the clearance makes the device newly relevant to roughly 5.5 million U.S. adults who manage type 2 diabetes with insulin — a market-sizing figure from the company, not an independently audited estimate.

What this outlet could not independently confirm

The specific 510(k) number and submission date for this clearance were not identified in the trade coverage reviewed for this story, and FDA's own device database was not directly accessible from this reporting environment. The trial statistics above are drawn from company-sourced reporting republished across multiple trade outlets rather than from an independent clinical publication; readers relying on these figures for submission strategy should confirm them against FDA's 510(k) summary once posted.

Frequently asked questions

What did FDA clear, and when?

On 16 October 2026, an expanded indication for Sequel Med Tech's twiist automated insulin delivery system, extending use to adults 18 and older with insulin-treated type 2 diabetes. Twiist was first cleared in March 2024 for people 6 and older with type 1 diabetes.

What evidence supported the expansion?

A 13-week, 307-participant trial in people with insulin-treated type 2 diabetes. HbA1c improved by about 0.7 points; time in the 70–180 mg/dL range rose from 57% to 73%; no severe hypoglycemia events were reported.

What does the device do, and what does it work with?

An automated insulin delivery system with a 300-unit reservoir, compatible with Abbott's FreeStyle Libre 3 Plus and Senseonics' Eversense 365 continuous glucose monitors.

Is this the first AID system cleared for type 2 diabetes?

No — Insulet's Omnipod 5 and Tandem's t:slim X2 already hold that indication. Twiist's clearance, via the same 510(k) pathway, adds a third major system to the category.